SPONSOR
Liu Huang
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2
Conditions studied: Lung CancerBreast CancerGastric CancerColorectal CancerMetastatic Colorectal Cancer
Liu Huang is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Liu Huang
How many clinical trials has Liu Huang sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Liu Huang, of which 3 are actively recruiting participants. These trials cover conditions including Lung Cancer, Breast Cancer, Gastric Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Liu Huang research focus on?
Liu Huang clinical trials span Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer, Metastatic Colorectal Cancer. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Liu Huang clinical trial?
To participate in a Liu Huang trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Liu Huang trials with current recruitment status updated daily.
Clinical Trials by Liu Huang
NCT06413212
Recruiting
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
Lung Cancer
NCT06980532 Phase 1, Phase 2
Recruiting
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
NCT06551207
Recruiting
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Metastatic Colorectal Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology